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Background: This study is to explore the pathological features of transplanted tumor established by CD133 positive
TJ905 glioblastoma stem-like cells.
Methods: CD133 positive TJ905 glioma cells were separated by immunomagnetic beads to isolate glioma stem-like
cells. TJ905 cells and stem-like cells were inoculated subcutaneously into the mice to establish model of transplanted
tumor, respectively. Mice growing condition and behavior were observed. HE staining assay, immunohistochemical
assay for GFAP, Ki-67 and Olig-2, and CD34 marked microvascular density (MVD) test were performed.
Results: The growing condition and behavior of mice in TJ905 stem cell group was more exaggerated and the models
showed stronger malignant features pathologically than that in TJ905 cell group. Glial fibrillary acidic protein (GFAP) in
TJ905 cell and stem-like cell group showed the transplanted tumor originated from astrocytes. Expression of Ki-67 and
oligodendrocyte transcription factor-2 (Olig-2) in TJ905 stem cells was higher notably and CD34 expression in stem cell
group was significantly higher than that in the other two groups.
Conclusions: Pathological features of transplanted tumor established by CD133 positive glioblastoma stem-like cells
show more malignant. Use of TJ905 stem cells to establish transplanted tumor model in nude mice is excellent for
glioma research.
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Glioblastoma Multiforme (GBM) is the most common
adult primary malignant brain tumors. Despite only
1.5 % in all tumors, GBM is the most lethal tumor [1].
Although the best option, standard surgical resection
with radiotherapy and chemotherapy, is performed, the
median survival time of patients is 12 to 18 months and
most patients died within 2 years after diagnosis [2].
Currently the strategy to cure glioblastoma is still facing
great challenges, especially drug resistance and tumor
recurrence after treatment [3]. It is necessary to find* Correspondence: chinesemd@hotmail.com
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glioblastoma at molecular and cellular levels.
Current evidence indicates that a subpopulation of
cancer cells, named cancer stem cells (CSCs) or tumor-
initiating cells which are responsible for the initiation,
growth, metastasis, therapy resistance and recurrence of
cancers, share core regulatory pathways with normal
stem cells but rely on distinct reprogrammed pathways
to maintain stemness and to contribute to the progres-
sion of cancers [4]. In recent years, many studies found
that there are a small group of cancer stem-like cells in
glioblastoma multiforme and they have features similar
to normal neural stem cells, such as self-renewal and
differentiation capacity. The group of cells might be an
important cause for recurrence of GBM and resistance
to chemotherapy [5]. Those glioma stem cells show
characteristics including higher tumorigenic potential,distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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specific genes of neural stem cell [6]. As many muta-
tions in the genome of most common glioma cell lines,
it is postulated that the cancer stem-like cells can estab-
lish a more representative GBM model like the primary
tumor in genotype [7, 8].
Thereby, we used CD133+ GBM cancer stem-like cells
to establish animal models, in order to provide a new ex-
perimental platform with more similarity to the charac-
teristics of primary cancer. In our study, glioma stem
cells were injected into nude mice subcutaneously for
setting up implanting tumor model. Tumor growth con-
dition, behavioral changes, histopathology and immuno-
histochemical staining was observed in the model to
improve the further understanding of glioblastoma on
cancer etiology, gene therapy and pharmacodynamics.
Materials and methods
Chemicals and reagents
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture
F-12 Ham’s (DMEM/F12) with high glucose medium was
purchased from HyClone (Logan, UT). Fetal bovine serum
(FBS), trypsin, B-27 (1×) Serum-Free Supplements was
from Gibico (Grand Island, NY). Epidermal growth factor
(EGF), basic fibroblast growth factor (bFGF), leukemia in-
hibitory factor (LIF) was obtained from Peprotech (Rocky
Hill, NJ). CD133 magnetic activated cell sorting (MACS)
kit was taken from Miltenyi Biotec GmbH (Bergisch
Gladbach, Germany). The hematoxylin and eosin (HE)
staining kit was provided from Boster Biological Tech-
nology, Ltd (Wuhan, China). SP immunohistochemistry kit
was offered from Zhongshan Goldenbridge Biotechnology
Co., Ltd (Beijing, China).
Cell culture of TJ905 cells
The TJ905 cell line was established and characterized
by Tianjin Neurological Institute laboratory of Neuro-
oncology [9]. TJ905 cell line was purchased from China
center for typical culture collection (CCTCC). TJ905
cells were cultured in DMEM/F12 medium with 10 %
FBS, 100U/ml penicillin and 100ug/ml streptomycin.
The culture was in a 37 °C, 5 % CO2 saturated humidity
incubator.
Isolation and culture of TJ905 stem cells
TJ905 cell line was cultured with medium for neural
stem cell including DMEM/F12,20 ng/ml EGF, 20 ng/ml
bFGF, 10 ng/ml LIF and B27(1X). The culture was in a
37 °C, 5 % CO2 saturated humidity incubator with
renewing medium for every 3–4 days. After a large
group of spheres of stem cells appeared, the spheres
were collected and MACS was used to isolate CD133+
cells [10].Animals
Thirty-five male 5-week old nude mice with 10–15 g
weight were purchased from Hubei Provincial Experi-
mental Animal Center. All animal study protocols were
approved by internationally accepted principles and the
Guidelines for the Care and Use of Laboratory Animals
of Huazhong University of Science and Technology [11].
Animal grouping
The animals were divided into 4 groups, TJ905 cell
group, TJ905 stem cell group, TJ905 CD133- group and
normal control group. The former three groups were
prepared by 10 mice in each group and the latter was
given 5 mice for experiment. The mice in TJ905 cell
group were injected with 1.0 × 106 cells and in TJ905
stem cell group the mice were given 5000 stem cell
spheres, while the mice in normal control were treated
by D-hanks solution with equal volume [8].
Cells inoculated subcutaneously in nude mice
After weighing, 3 % iodine and 75 % alcohol was used to
sterilize the abdomen and right thigh puncture site. The
nude mice were injected peritoneally with 10 % chloral-
hydrate 0.3 ml per 100 g for anesthesia. Then 100 μl 106
cell suspension was inoculated at the right thigh sub-
cutaneously by microlitre syringe with 1 μl/min speed
slowly. Prior to withdrawing, the needle stayed for 5 min
in order for deposition of the cells. The whole procedure
was performed in a sterile environment and no use of
antibiotics.
Observation on mice growing condition and behavior
The inoculated mice were fed and observed in Experi-
mental Animal Center of Tongji Medical College. The
weight, skin cleanness, drinking and eating, activity
and semiplegia of the mice were observed.
Measurement of transplanted tumor size
At each 3 days after 7th day of inoculation, the subcuta-
neous neoplasms of nude mice in 2 model groups were
measured by caliper rule, respectively. The tumor diam-
eter was measured and tumor size was calculated. Tumor
sizes in the two groups were compared.
Sample collection
Twenty-one day after the inoculation of cells or spheres,
each mouse in first three groups was injected 10 %
chloralhydrate for hyperanesthesia. 5 mice in TJ905 cell
and stem cell group were injected 10 % chloralhydrate
for hyperanesthesia. The mice were executed and tumor
tissue was taken out. The tissue was washed with cold
normal saline and conserved in liquid nitrogen tank
quickly for test. The rest tissue was fixed quickly with
4 % paraformaldehyde for 2–4 h and then was placed in
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embedded with paraffin. The heart, liver, lung, spleen,
kidneys, and spinal cord were also taken for examination
to confirm whether metastasis occurred. The samples
in normal control group were taken at the end of
experiment.
HE staining assay
Paraffin-embedded tissues were cut to 4 μm slices and
were deparaffinate in dimethylbenzene for 5–10 min.
Then the tissues were put into 100 %, 95 %, 85 % and
70 % alcohol for 2–5 min in turn and finally washed by
distilled water and immersed into staining solution.
After hematoxylin staining for 5–15 min, the excess
stain solution on the slides was washed, and colorsepera-
tion with 0.5–1 % hydrochloride alcohol (made by 75 %
alcohol) was performed for about 10 s. Following washed
with running water for 15–30 min, the tissues were
stained by 0.1 ~ 0.5 % eosin for 1–5 min. Prior to hyali-
nized with dimethylbenzene twice for about 10 min in
total, the tissues were dehydrated with 75 %, 85 %, 95 %,
100 % alcohol for 2–3 min in turn. At last slipp was
droped by neutral gum and covered by slide. As a result,
nucleuses were blue and cytoplasm, collagen fibers
showed different red or pink.
Immunohistochemical assay on GFAP, Ki-67 and Olig-2
Streptavdin-peroxidase-biotin (SP) method was used for
immunohistochemistry. The slides were deparaffinated
conventionally and were immersed with 3 % H2O2 for
10 min to block endogenous peroxidase. After antigen
retrieval by microwave, new-born calf serum was added
for blocking for 10 min, and then first antibody (GFAP
1:50, Ki-67 and Olig-2 primary concentration) was
added to incubate overnight (4 °C) and secondary anti-
bodies to incubate for 20 min at room temperature.
Then streptavidin-biotin-peroxidase solution was used
to incubate for 30 min and 3,3′-diaminobenzidine
(DAB) was added to chlorate for 15 min. Followed by
hematoxylin staining, dehydration and hyalinization, the
slip was covered. In the negative control, first antibody
was replaced by phosphate buffered saline (PBS). As a
result, glial fibrillary acidic protein (GFAP), Ki-67 and
oligodendrocyte transcription factor-2 (Olig-2) positive
staining located in the cytoplasm and cell protrusion
and showed brown. The slices were observed in high
power microscopy and positive cell counting in each 50
visual fields were averaged.
CD34 marked microvascular density (MVD) test
CD34 expresses in vascular endothelial cells, tumor
cytoplasm or membrane and is used to a specific marker
of vascular endothelial cell. Immunohistochemical stain-
ing makes it show a distribution of brown or light brownsolid bud-like or cord-like blood vessels. For observa-
tion, the fields at which tumor micrangium count was
most at low magnification vision were selected, and then
the vascular endothelial cells or cell group which showed
brown or sepia at high magnification (×200 times) were
counted. One should be counted as independent micran-
gium on condition of obvious distinction from neighbor
micrangium and tumorous cell. 5 counts of micrangium
of each slide at high magnification vision were recorded,
and the average was taken as the MVD.
Statistical analysis
Measurement data shows as mean ± SD. Group com-
parison was compared with one-way ANOVA analysis.
Significance was considered when P < 0.05. All the data
were analyzed with SPSS 12.0.
Results
Mice growing condition
In TJ905 cell group, at 2 days after inoculation the appe-
tite and foraging ability of mice increased and weight
gradually rose. At 13–17 days after inoculation the mice
started to show depressed with reduced activity, tarn-
ished skin, and a little decline of foraging and eating
ability. At 17 days after inoculation the symptom signifi-
cantly aggravated. In TJ905 stem cell group, at 2 days
after inoculation the living condition was similar to that
in TJ905 cell group. At 10–12 days after inoculation, the
mice showed similar manifestation to that in TJ905 cell
group and additionally skin gradually became dark gray
and weight loss occurred. At 13 days after inoculation
the symptom significantly worsened with cachexia. In
TJ905CD133- group, the mice growing condition and
behavior were similar to that in TJ905 cell group. In nor-
mal control group, 2 days after inoculation, the mice
returned to normal eating and drinking with obvious
weight gain. They survived well without symptom and
death (Fig. 1a-d). The curves of tumor growth were de-
scribed in Fig. 1e.
Tumor growth
The sorting rate of CD133+ cell was 0.64–0.91 %. Both
tumor forming rate of TJ905 cell and stem cell group
was 100 %. The tumor growth was infiltrative with
round or oval shape and envelope could be observed,
and the tumor showed darker color than the normal tis-
sue around. The facet of tumor was fish-like with
hemorrhage and necrosis. When the tumor grew big
enough, the margin of tumor in TJ905 cell group and
TJ905 CD133- group were clear, while in TJ905 stem cell
group the boundary was significantly less clear. All in
TJ905 cell, TJ905 CD133- and stem cell group there was
no metastasis in peritoneal cavity. Normal control group
showed no tumor formation.
Fig. 1 Observation on mice appearance. The pictures were shot at 14th post-injection day. a The mice in TJ905 cell group showed tarnished skin
with depression; b The mice in TJ905 stem cell group showed similar manifestation to that in TJ905 cell group and additionally skin gradually
became dark gray and weight loss occurred; c The mice in normal control group showed lustrous skin; d The mice in TJ905 CD133- cell group
showed similar manifestation to that in TJ905 cell group; e The tumor size in stem-like cell group showed significantly larger than in TJ905 cell group
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At 7, 10, 13, 16, 19, 21 days after inoculation comparison
of tumor size between TJ905 cell, and stem cell group
was significantly different (P <0.05). The tumor size in
TJ905 stem cell group was much larger.
Pathological morphology
In TJ905 cell group, after HE staining the transplanted
tumor showed round or spindle-shape with dense ar-
rangement under light microscope, accompanied with
big nucleolus, inversion of nucleus-cytoplasm rate, obvi-
ous nuclear atypia. Pathological caryokinesis, low-degree
differentiation implied high degree in malignancy. Al-
though tumor cell growth was infiltrative, there was still
an obvious boundary between tumor and normal tissue.
The pathological features in TJ905 CD133- group were
similar to that in TJ905 cell group. In TJ905 stem cell
group, the cells showed pseudo-barrier-like or coral-likearrangement and dense clusters, infiltrating into normal
subcutaneous tissue. Infiltration of tumor cell could be
seen at the boundary between tumor and normal tissue,
and the boundary was blurred. Cystolization, necrosis and
formation of neonatal vessel in the tumor center showed
stronger malignant transformation. In normal control
group, the staining showed skeletomuscular cells (Fig. 2).
GFAP staining
GFAP staining in TJ905 cell, TJ905 CD133- and stem cell
group were positive, showing buffy or brown. The positive
rate in TJ905 stem cell group was significantly higher than
that in TJ905 cell and CD133- group (P < 0.05) (Fig. 3).
Ki-67 staining
KI-67 is a nuclear protein that is associated with cellular
proliferation. Ki-67 is an excellent marker to determine
the growth fraction of tumor cells, which is often
Fig. 2 Observation on pathological morphology (×20). a In TJ905 cell group there was obvious boundary between normal tissue and tumor; b In
TJ905 stem cell group the boundary between normal tissue and tumor was blurred; the cells showed pseudo-barrier-like or coral-like arrangement
and dense clusters with necrosis, infiltrating into normal tissue; c In normal control group, skeletomuscular tissue was presented; d The mice in
TJ905 CD133- cell group showed similar manifestation to that in TJ905 cell group
Fig. 3 GFAP staining (×40). a The positive cells of GFAP staining in TJ905 cell group presented brown; b The positive cells of GFAP staining in
TJ905 stem cell group also showed brown but were more than the cells in TJ905 cell group; c Skeletomuscular tissue was shown in normal
control group; d The mice in TJ905 CD133- cell group showed similar manifestation to that in TJ905 cell group
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the carcinomas of brain. Ki-67 staining in TJ905 cell,
TJ905 CD133- and stem cell group were positive, show-
ing buffy or brown. The positive rate in TJ905 stem cell
group was significantly higher than that in TJ905 cell
and CD133- group (P < 0.05) (Fig. 4).
Olig-2 staining
Olig-2 is universally expressed in diffuse gliomas and
serves as a diagnostic marker for brain tumor, especially
for highly tumorigenic gliomas. Olig-2 staining in TJ905
cell, TJ905 CD133- and stem cell group were positive,
showing buffy or brown. The positive rate in TJ905 stem
cell group was significantly higher than that in TJ905
cell and CD133- group (P < 0.05) (Fig. 5).
CD34 staining
CD34 expresses in vascular endothelial cells, tumor
cytoplasm or membrane. Average of MVP in TJ905 stem
cells group was significantly higher than that in TJ905
cell and CD133- group (P < 0.05). Most capillaries of
tumor tissue and cytoplasm structure were abnormal,
and the basement membrane was incomplete or even
constituted by only a single cell or only by blood tunnel.
Some “blood vessels” were constituted by tumor cells
and endothelium (Fig. 6).
Discussion
Malignant gliomas are the most common primary neu-
roectodermal tumor, accounting for 15–23 % intracra-
nial tumors in adults and about 50 % of all primaryFig. 4 Ki-67 staining (×40). a The positive cells of Ki-67 staining in TJ905 ce
TJ905 stem cell group were significantly more than that in TJ905 cell group
rare; d The mice in TJ905 CD133- cell group showed similar manifestationbrain tumors. Despite technological progress in surgery,
chemotherapy and radiotherapy, the rapid growth of
tumor, invasive proliferation, and angiogenesis with high
density make glioblastoma multiforme poor prognosis
[12]. Although the specific mechanisms of cancer stem-
like cells are still unclear, the theory will help us under-
stand the formation of glioma. It can be postulated that
the cancer stem-like cells will become a potential new
target for cancer treatment [13].
Although various malignant glioma models have been
established, the models created by traditional xenograft
cell lines show limited invasiveness and heterogeneity, and
changes of pathological characteristics for human gliomas.
Recently, cancer stem-like cells isolated from surgical
specimens were used to set up new animal model, which
showed more similar characteristics of human cancer [14].
Therefore, it is necessary to explore the model established
by glioma stem cells in order to study characteristics of
glioma and provide an ideal platform to address the mech-
anisms of tumor recurrence and chemoresistance.
It was reported that tumor could be formed when
NOD-SCID nude mice was injected 100 CD133+ cells
extracted from cancer tissue, but injection with 100,000
CD133- cells did not form tumors. That heterogeneity
showed only a small part of cancer cells might be a key
for tumor recurrence, and targeted treatment of those
cells might be new innovative method to eradicate the
tumor [15]. We used CD133+ TJ905 stem cells injected
subcutaneously in nude mice to form glioma model,
which provided a vector for studying the characteristics
of malignant glioma.ll group presented brown; b The positive cells of Ki-67 staining in
; c The positive cells of Ki-67 staining in normal control group were
to that in TJ905 cell group
Fig. 5 Olig-2 staining (×40). a The positive cells of Olig-2 staining in TJ905 cell group presented brown; b The positive cells of Olig-2 staining in
TJ905 stem cell group were significantly more than that in TJ905 cell group; c The positive cells of Olig-2 staining in normal control group were
rare; d The mice in TJ905 CD133- cell group showed similar manifestation to that in TJ905 cell group
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TJ905 cells and stem cells, and all of experimental ani-
mals formed tumor. Compared with model of TJ905
cells, the model of glioma stem cells showed great differ-
ences in growth and behavior condition, such as weight
loss, activity, skin, foraging and eating ability, cachexia,
survival rate and exudate. The tumor weight, growthFig. 6 CD34 staining (×40). a The positive cells of CD34 staining in TJ905 c
TJ905 stem cell group were significantly more than that in TJ905 cell group
notably less than that in the other two groups; d The mice in TJ905 CD133time and pathological examination also matched these
findings.
GFAP, an intermediate fibrous protein, is a marker of
astrocyte and a symbol of differentiation into mature
cells from brain tumor stem cells [16]. In our study, both
of the tumor models by TJ905 cells and stem cells highly
expressed GFAP, indicating that the tumor originatedell group presented brown; b The positive cells of CD34 staining in
; c The positive cells of CD34 staining in normal control group were
- cell group showed similar manifestation to that in TJ905 cell group
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Ki-67 index is a marker of proliferation in malignant tu-
mors, especially brain cancers, as it can be detected dur-
ing all the active phases of cell cycle but is absent in
resting cells [17]. It is commonly used as a complement
to grading systems that include mitotic counting as a
sign of proliferation [18]. Olig-2 is well recognized as a
diagnostic marker for brain tumor, for it is required for
proliferation of human glioma cells [19]. In our research,
significant expression of Ki-67 and Olig-2 was observed
in TJ905 cells and was much higher in TJ905 stem cells,
which demonstrated that the malignant degree in cancer
stem-like cells.
CD34 is a salivary mucin on cell surface and widely
used to purify hematopoietic stem cells and as a marker
of most capillary endothelial cells. Angiogenesis is not
only an important process involved in the normal
growth and differentiation, but necessary for develop-
ment of a tumor. The higher the degree of malignancy
is, with the faster the growth, the more adequate supply
of oxygen and nutrients are needed. MVD (microvessel
density) of tumor may indirectly reflect growth, invasion
and metastasis of tumor tissue [20]. Thereby MVD is
used to determine the grade and prognosis of malignant
tumor. In our study, in TJ905 stem cell group the
CD34 expression was much higher than that in TJ905
cell group, which also shows the transplanted tumor
that originates from cancer stem-like cell has a stron-
ger malignance.
In summary, the tumor model from CD133+ GBM
stem-like cells showed the features from astrocytes with
high malignance. Based on our previous researches [21,
22], we established xenograft tumor model by using
TJ905 cells and stem cells, and found the animal model
from glioma stem cells might exhibit more malignant
characteristics in the detected markers. We would fur-
ther explore the molecular mechanisms of this GBM
animal model in the future in order to find a platform
for faithfully mirroring clinical practice.
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